Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$18.7M Buy
40,056
+19,055
+91% +$8.01M 0.02% 755
2026
Q1
$7.93M Buy
21,001
+12,919
+160% +$5.53M 0.01% 1141
2025
Q4
$3.46M Buy
+8,082
New +$3.52M ﹤0.01% 1589
2025
Q2
Sell
-6,252
Closed -$3.85M 2878
2025
Q1
$3.85M Sell
6,252
-10,691
-63% -$6.08M 0.01% 1379
2024
Q4
$8.98M Buy
+16,943
New +$9.55M 0.01% 1011
2024
Q2
Sell
-2,563
Closed -$1.65M 2628
2024
Q1
$1.65M Buy
+2,563
New +$1.56M ﹤0.01% 1604
2022
Q2
Sell
-570
Closed -$289K 2788
2022
Q1
$289K Buy
+570
New +$273K ﹤0.01% 1933
2020
Q1
Sell
-6,121
Closed -$2.69M 1197
2019
Q4
$2.69M Buy
+6,121
New +$2.57M 0.02% 703
2019
Q3
Sell
-3,569
Closed -$1.29M 1212
2019
Q2
$1.29M Sell
3,569
-7,095
-67% -$2.37M 0.01% 1010
2019
Q1
$3.41M Buy
10,664
+5,728
+116% +$1.76M 0.02% 667
2018
Q4
$1.4M Buy
4,936
+780
+19% +$235K 0.01% 812
2018
Q3
$1.33M Sell
4,156
-4,763
-53% -$1.52M 0.01% 1101
2018
Q2
$2.87M Buy
+8,919
New +$2.79M 0.01% 821
2018
Q1
Sell
-4,863
Closed -$1.18M 1976
2017
Q4
$1.18M Buy
4,863
+3,365
+225% +$764K ﹤0.01% 1292
2017
Q3
$303K Buy
+1,498
New +$294K ﹤0.01% 1531

Other funds holding CHE

Dmitry Balyasny's CHE Position: Q2 2026 in Review

Dmitry Balyasny increased its Chemed (CHE) stake by 91% in Q2 2026, buying an estimated $8.01M and bringing the position to 40,056 shares worth $18.7M. The position accounts for 0.02% of the portfolio, ranked #755.

Dmitry Balyasny first reported a position in CHE in Q3 2017 and has held it in 15 quarters since. 528 funds tracked by Wall St. Rank hold CHE as of Q2 2026.

  • Dmitry Balyasny held 40,056 shares of Chemed worth $18.7M as of Q2 2026.
  • Dmitry Balyasny bought 19,055 Chemed shares in Q2 2026, an estimated $8.01M.
  • Chemed made up 0.02% of Dmitry Balyasny's portfolio in Q2 2026, its #755 holding.
  • Dmitry Balyasny first reported a position in Chemed in Q3 2017 and has held it in 15 quarters since.
  • 528 funds tracked by Wall St. Rank held Chemed as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.